Does COVID-19 Provide a Clue for Thrombosis in ITP?

Abstract

Letter to the Editor 463This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine

“…Due to ITP manifestations in asymptomatic COVID‐19 patients, these cases likely underestimate their real occurrence 1,3 . Some authors even postulated a causal relationship between a prothrombotic state in ITP patients and SARS‐CoV‐2 infections, leading to a highly delicate and challenging situation 4 . Similarly, AIHA is a probably underrated complication of COVID‐19, and Algassim et al 5 reported that lower hemoglobin levels are related to poorer prognosis in these patients.…”

“… 1 , 3 Some authors even postulated a causal relationship between a prothrombotic state in ITP patients and SARS-CoV-2 infections, leading to a highly delicate and challenging situation. 4 Similarly, AIHA is a probably underrated complication of COVID-19, and Algassim et al 5 reported that lower hemoglobin levels are related to poorer prognosis in these patients. These complications therefore represent an additional burden of a disease whose potentially severe clinical course mainly affects elderly patients.…”

The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties

“…Due to this prothrombotic state, anticoagulant therapy is recommended, and for which heparin therapy has now become routine practice for hospitalized patients with COVID-19. 11 This approach is aimed to mitigate the magnified risk of in situ pulmonary thrombosis, 12 venous thromboembolism, 13 arterial thrombosis, 14 as well as disseminated intravascular coagulation. 15 According to the Scientific and Standardization Committee Communication of the International Society of Thrombosis and Haemostasis, routine thromboprophylaxis with standard-dose unfractionated heparin (UFH) or preferably with low molecular weight heparin (LMWH) should be administered after assessment of bleeding risk in all non-intensive care unit (ICU) hospitalized patients with SARS-CoV-2 infection, while routine use of a prophylactic dose of LMWH (or UFH) should be administered to all ICU hospitalized COVID-19 patients.…”

Untitled

“…The rest of the issue contains several Letters to the Editor. [23][24][25][26][27][28][29][30][31] Such "correspondence" permits publication of var-ious "smaller" COVID-19 vignettes. First come two small cases series, the first of which discusses fatal disseminated intravascular coagulopathy (DIC) in COVID-19, 23 and the second of which discusses pulmonary thrombosis in COVID-19 treated by thrombolysis using streptokinase.…”